NICE yes for NSCLC diagnostic tests could impact Iressa and Tarceva
This article was originally published in Scrip
Executive Summary
New guidance from NICE, the health technology appraisal institute for England and Wales, recommending EGFR-tyrosine kinase mutation tests for routine use on the National Health Service could improve the treatment of non-small cell lung cancer treatment. It could also impact use of Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), the two EGFR-TK inhibitors recommended by NICE to treat NSCLC.
You may also be interested in...
WHO Launches Action Plan For Cross-Country Market Access Collaborations
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
EU Orphan Law Under Attack Over ‘Flawed Incentives’
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
UK Pulls Out Of Unified Patent Court Agreement
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.
Need a specific report? 1000+ reports available
Buy Reports